Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vivus Gets FDA Approval For Evamist Estradiol Spray

This article was originally published in The Pink Sheet Daily

Executive Summary

Approval triggers $140 million payment from KV Pharmaceutical, which licensed the product in March.
Advertisement

Related Content

KV Purchases Hologic Premature Birth Prevention Candidate; Sale Contingent On FDA Approval
KV Purchases Hologic Premature Birth Prevention Candidate; Sale Contingent On FDA Approval
Columbia Expands Prochieve's Reach Beyond Infertility Market With Ascend License Agreement
Columbia Expands Prochieve's Reach Beyond Infertility Market With Ascend License Agreement
Vivus Sells EvaMist Rights To KV For $150 Million
Vivus Sells EvaMist Rights To KV For $150 Million
BioSante To Launch Hot Flash Drug Elestrin in 2007

Topics

Advertisement
UsernamePublicRestriction

Register

PS066402

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel